Abstract
Treatment with glatiramer acetate (GA) modestly decreases disease activity in multiple sclerosis (MS). The mechanism of action is incompletely understood and differences in the response to treatment between individuals may exist.
Original language | English |
---|---|
Journal | Multiple sclerosis |
Volume | 19 |
Issue number | 2 |
Pages (from-to) | 179-87 |
Number of pages | 9 |
ISSN | 1352-4585 |
DOIs | |
Publication status | Published - Feb 2013 |
Keywords
- Adult
- Antigen-Presenting Cells
- Antigens, CD40
- CD4-Positive T-Lymphocytes
- Dendritic Cells
- Female
- Flow Cytometry
- HLA-DRB1 Chains
- Humans
- Immunosuppressive Agents
- Lymphocyte Activation
- Lymphocyte Count
- Macrophage Activation
- Magnetic Resonance Imaging
- Male
- Middle Aged
- Monocytes
- Multiple Sclerosis
- Peptides
- Recurrence
- T-Lymphocytes
- Young Adult